{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:04:09Z","timestamp":1792019049084,"version":"4.4.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Major Program of National Natural Science Foundation of China","award":["82293634"],"award-info":[{"award-number":["82293634"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300252"],"award-info":[{"award-number":["82300252"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470171"],"award-info":[{"award-number":["82470171"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970161"],"award-info":[{"award-number":["81970161"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170163"],"award-info":[{"award-number":["82170163"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970147"],"award-info":[{"award-number":["81970147"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022A1515110828"],"award-info":[{"award-number":["2022A1515110828"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2022M721498"],"award-info":[{"award-number":["2022M721498"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06608-x","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T15:59:06Z","timestamp":1748361546000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy and safety of third-generation CD19-CAR T cells incorporating CD28 and TLR2 intracellular domains for B-cell malignancies with central nervous system involvement: results of a pivotal trial"],"prefix":"10.1186","volume":"23","clinical-trial-number":[{"clinical-trial-number":"nct04605666","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Bailin","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongsheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4015-3952","authenticated-orcid":false,"given":"Qifa","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"6608_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2018.01.073","volume":"93","author":"TC El-Galaly","year":"2018","unstructured":"El-Galaly TC, Cheah CY, Bendtsen MD, Nowakowski GS, Kansara R, Savage KJ, et al. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. Eur J Cancer. 2018;93:57\u201368.","journal-title":"Eur J Cancer"},{"issue":"12","key":"6608_CR2","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1182\/blood.2022017035","volume":"141","author":"NE Kopmar","year":"2023","unstructured":"Kopmar NE, Cassaday RD. How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia. Blood. 2023;141(12):1379\u201388.","journal-title":"Blood"},{"key":"6608_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217264","volume":"605","author":"Y Wang","year":"2024","unstructured":"Wang Y, Chang YJ, Chen J, Han M, Hu J, Hu J, et al. Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update. Cancer Lett. 2024;605: 217264.","journal-title":"Cancer Lett"},{"issue":"10","key":"6608_CR4","doi-asserted-by":"publisher","first-page":"e1027","DOI":"10.1212\/WNL.0000000000008900","volume":"94","author":"C Houillier","year":"2020","unstructured":"Houillier C, Soussain C, Ghesquieres H, Soubeyran P, Chinot O, Taillandier L, et al. Management and outcome of primary CNS lymphoma in the modern era: an LOC network study. Neurology. 2020;94(10):e1027\u201339.","journal-title":"Neurology"},{"issue":"4","key":"6608_CR5","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/bjh.18537","volume":"200","author":"M Dargenio","year":"2023","unstructured":"Dargenio M, Bonifacio M, Chiaretti S, Vitale A, Fracchiolla NS, Papayannidis C, et al. Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric-inspired regimens: a retrospective multicentre Campus ALL study. Br J Haematol. 2023;200(4):440\u201350.","journal-title":"Br J Haematol"},{"issue":"1","key":"6608_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20(1):31\u201342.","journal-title":"Lancet Oncol"},{"issue":"5","key":"6608_CR7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"issue":"2","key":"6608_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22(2):85\u201396.","journal-title":"Nat Rev Immunol"},{"issue":"20","key":"6608_CR9","first-page":"2430","volume":"141","author":"MD Jain","year":"2023","unstructured":"Jain MD, Smith M, Shah NN. How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood. 2023;141(20):2430\u201342.","journal-title":"Blood"},{"issue":"8","key":"6608_CR10","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJMc1704610","volume":"377","author":"JS Abramson","year":"2017","unstructured":"Abramson JS, McGree B, Noyes S, Plummer S, Wong C, Chen YB, et al. Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma. N Engl J Med. 2017;377(8):783\u20134.","journal-title":"N Engl J Med"},{"issue":"11","key":"6608_CR11","doi-asserted-by":"publisher","first-page":"E301","DOI":"10.1002\/ajh.27051","volume":"98","author":"K Sanber","year":"2023","unstructured":"Sanber K, Ly A, Ondo A, Mooney K, Baker J, Shedeck A, et al. Outpatient CD28-costimulated CAR T-cells for B-cell malignancies with CNS involvement. Am J Hematol. 2023;98(11):E301\u20134.","journal-title":"Am J Hematol"},{"issue":"11","key":"6608_CR12","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1182\/blood.2019001694","volume":"134","author":"MJ Frigault","year":"2019","unstructured":"Frigault MJ, Dietrich J, Martinez-Lage M, Leick M, Choi BD, DeFilipp Z, et al. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 2019;134(11):860\u20136.","journal-title":"Blood"},{"issue":"15","key":"6608_CR13","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1182\/blood.2021014738","volume":"139","author":"MJ Frigault","year":"2022","unstructured":"Frigault MJ, Dietrich J, Gallagher K, Roschewski M, Jordan JT, Forst D, et al. Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1\/2 clinical trial. Blood. 2022;139(15):2306\u201315.","journal-title":"Blood"},{"key":"6608_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102931","volume":"58","author":"J Jayaraman","year":"2020","unstructured":"Jayaraman J, Mellody MP, Hou AJ, Desai RP, Fung AW, Pham AHT, et al. CAR-T design: elements and their synergistic function. EBioMedicine. 2020;58: 102931.","journal-title":"EBioMedicine"},{"key":"6608_CR15","doi-asserted-by":"publisher","first-page":"251513552092716","DOI":"10.1177\/2515135520927164","volume":"8","author":"L Halim","year":"2020","unstructured":"Halim L, Maher J. CAR T-cell immunotherapy of B-cell malignancy: the story so far. Ther Adv Vaccines Immunother. 2020;8:2515135520927164.","journal-title":"Ther Adv Vaccines Immunother"},{"issue":"12","key":"6608_CR16","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1016\/j.ymthe.2018.09.009","volume":"26","author":"CA Ramos","year":"2018","unstructured":"Ramos CA, Rouce R, Robertson CS, Reyna A, Narala N, Vyas G, et al. Fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin\u2019s lymphomas. Mol Ther. 2018;26(12):2727\u201337.","journal-title":"Mol Ther"},{"issue":"9","key":"6608_CR17","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0813101106","volume":"106","author":"C Carpenito","year":"2009","unstructured":"Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA. 2009;106(9):3360\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"6608_CR18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13045-023-01470-0","volume":"16","author":"ML Schubert","year":"2023","unstructured":"Schubert ML, Schmitt A, Huckelhoven-Krauss A, Neuber B, Kunz A, Waldhoff P, et al. Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial. J Hematol Oncol. 2023;16(1):79.","journal-title":"J Hematol Oncol"},{"issue":"11","key":"6608_CR19","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1038\/s41375-024-02392-7","volume":"38","author":"P Derigs","year":"2024","unstructured":"Derigs P, Schubert ML, Dreger P, Schmitt A, Yousefian S, Haas S, et al. Third-generation anti-CD19 CAR T cells for relapsed\/refractory chronic lymphocytic leukemia: a phase 1\/2 study. Leukemia. 2024;38(11):2419\u201328.","journal-title":"Leukemia"},{"issue":"3","key":"6608_CR20","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/leu.2017.249","volume":"32","author":"Y Lai","year":"2018","unstructured":"Lai Y, Weng J, Wei X, Qin L, Lai P, Zhao R, et al. Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T cells. Leukemia. 2018;32(3):801\u20138.","journal-title":"Leukemia"},{"issue":"2","key":"6608_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-034629","volume":"10","author":"P George","year":"2020","unstructured":"George P, Dasyam N, Giunti G, Mester B, Bauer E, Andrews B, et al. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE). BMJ Open. 2020;10(2): e034629.","journal-title":"BMJ Open"},{"key":"6608_CR22","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1182\/blood-2023-178872","volume":"142","author":"R Weinkove","year":"2023","unstructured":"Weinkove R, George P, Fyfe R, Dasyam N, Nouri Y, Ostapowicz T, et al. A phase 1 dose escalation trial of third-generation CD19-directed CAR T-cells incorporating CD28 and Toll-like Receptor 2 (TLR2) intracellular domains for relapsed or refractory B-cell non-hodgkin lymphomas (ENABLE). Blood. 2023;142:890.","journal-title":"Blood"},{"key":"6608_CR23","doi-asserted-by":"crossref","unstructured":"Weng JY, Lai PL, Qin L, Lai YX, Jiang ZW, Luo CW, et al. A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia. J Hematol Oncol. 2019;12(1).","DOI":"10.1186\/s13045-019-0816-4"},{"issue":"1","key":"6608_CR24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbmt.2018.09.024","volume":"25","author":"Z Mahmoudjafari","year":"2019","unstructured":"Mahmoudjafari Z, Hawks KG, Hsieh AA, Plesca D, Gatwood KS, Culos KA. American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group Survey on chimeric antigen receptor T cell therapy administrative, logistic, and toxicity management practices in the United States. Biol Blood Marrow Transplant. 2019;25(1):26\u201333.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"27","key":"6608_CR25","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368.","journal-title":"J Clin Oncol"},{"issue":"10","key":"6608_CR26","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.6004\/jnccn.2015.0153","volume":"13","author":"JC Alvarnas","year":"2015","unstructured":"Alvarnas JC, Brown PA, Aoun P, Ballen KK, Barta SK, Borate U, et al. Acute lymphoblastic leukemia, Version 2.2015. J Natl Compr Canc Netw. 2015;13(10):1240\u201379.","journal-title":"J Natl Compr Canc Netw"},{"key":"6608_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.965224","volume":"13","author":"H Zhang","year":"2022","unstructured":"Zhang H, Yan Z, Wang Y, Qi Y, Hu Y, Li P, et al. Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma. Front Immunol. 2022;13: 965224.","journal-title":"Front Immunol"},{"issue":"18","key":"6608_CR28","doi-asserted-by":"publisher","first-page":"5316","DOI":"10.1182\/bloodadvances.2023010336","volume":"7","author":"F Ayuk","year":"2023","unstructured":"Ayuk F, Gagelmann N, von Tresckow B, Wulf G, Rejeski K, Stelljes M, et al. Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA\/DRST study. Blood Adv. 2023;7(18):5316\u20139.","journal-title":"Blood Adv"},{"issue":"1","key":"6608_CR29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-023-01508-3","volume":"16","author":"N Epperla","year":"2023","unstructured":"Epperla N, Feng L, Shah NN, Fitzgerald L, Shah H, Stephens DM, et al. Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study. J Hematol Oncol. 2023;16(1):111.","journal-title":"J Hematol Oncol"},{"issue":"23","key":"6608_CR30","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1182\/blood.2021013733","volume":"139","author":"Y Qi","year":"2022","unstructured":"Qi Y, Zhao M, Hu Y, Wang Y, Li P, Cao J, et al. Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL. Blood. 2022;139(23):3376\u201386.","journal-title":"Blood"},{"issue":"11","key":"6608_CR31","doi-asserted-by":"publisher","first-page":"e816","DOI":"10.1016\/S2352-3026(20)30277-5","volume":"7","author":"T Anagnostou","year":"2020","unstructured":"Anagnostou T, Riaz IB, Hashmi SK, Murad MH, Kenderian SS. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis. Lancet Haematol. 2020;7(11):e816\u201326.","journal-title":"Lancet Haematol"},{"issue":"21","key":"6608_CR32","doi-asserted-by":"publisher","first-page":"6883","DOI":"10.3390\/jcm12216883","volume":"12","author":"K Saleh","year":"2023","unstructured":"Saleh K, Pasquier F, Bigenwald C, De Botton S, Ribrag V, Castilla-Llorente C. CAR T-cells for the treatment of B-cell acute lymphoblastic leukemia. J Clin Med. 2023;12(21):6883.","journal-title":"J Clin Med"},{"key":"6608_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.904497","volume":"13","author":"AC Caballero","year":"2022","unstructured":"Caballero AC, Escriba-Garcia L, Alvarez-Fernandez C, Briones J. CAR T-cell therapy predictive response markers in diffuse large B-cell lymphoma and therapeutic options after CART19 failure. Front Immunol. 2022;13: 904497.","journal-title":"Front Immunol"},{"issue":"2","key":"6608_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","volume":"18","author":"KL Chohan","year":"2023","unstructured":"Chohan KL, Siegler EL, Kenderian SS. CAR-T cell therapy: the efficacy and toxicity balance. Curr Hematol Malig Rep. 2023;18(2):9\u201318.","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"6608_CR35","doi-asserted-by":"publisher","first-page":"2378543","DOI":"10.1080\/21645515.2024.2378543","volume":"20","author":"D Goyco Vera","year":"2024","unstructured":"Goyco Vera D, Waghela H, Nuh M, Pan J, Lulla P. Approved CAR-T therapies have reproducible efficacy and safety in clinical practice. Hum Vaccin Immunother. 2024;20(1):2378543.","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"6608_CR36","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","volume":"56","author":"VS Sheth","year":"2021","unstructured":"Sheth VS, Gauthier J. Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL. Bone Marrow Transplant. 2021;56(3):552\u201366.","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"6608_CR37","doi-asserted-by":"publisher","first-page":"e711","DOI":"10.1016\/S2352-3026(21)00238-6","volume":"8","author":"AB Leahy","year":"2021","unstructured":"Leahy AB, Newman H, Li Y, Liu H, Myers R, DiNofia A, et al. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials. Lancet Haematol. 2021;8(10):e711\u201322.","journal-title":"Lancet Haematol"},{"issue":"4","key":"6608_CR38","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","volume":"28","author":"Z Zhao","year":"2015","unstructured":"Zhao Z, Condomines M, van der Stegen SJC, Perna F, Kloss CC, Gunset G, et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell. 2015;28(4):415\u201328.","journal-title":"Cancer Cell"},{"issue":"9","key":"6608_CR39","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1073\/pnas.0400171101","volume":"101","author":"M Komai-Koma","year":"2004","unstructured":"Komai-Koma M, Jones L, Ogg GS, Xu DM, Liew FY. TLR2 is expressed on activated T cells as a costimulatory receptor. Proc Natl Acad Sci USA. 2004;101(9):3029\u201334.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"6608_CR40","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.cellsig.2012.11.026","volume":"25","author":"NM Chapman","year":"2013","unstructured":"Chapman NM, Bilal MY, Cruz-Orcutt N, Knudson C, Madinaveitia S, Light J, et al. Distinct signaling pathways regulate TLR2 co-stimulatory function in human T cells. Cell Signal. 2013;25(3):639\u201350.","journal-title":"Cell Signal"},{"key":"6608_CR41","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1182\/blood-2022-165256","volume":"140","author":"CA Jacobson","year":"2022","unstructured":"Jacobson CA, Falvey C, Bouvier R, Hogan S, Kendricken E, Jones J, et al. A pilot study of axicabtagene ciloleucel (axi-cel) for the treatment of relapsed\/refractory primary and secondary central nervous system lymphoma (CNSL). Blood. 2022;140:1060\u20131.","journal-title":"Blood"},{"issue":"6","key":"6608_CR42","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/s41375-022-01546-9","volume":"36","author":"E Jacoby","year":"2022","unstructured":"Jacoby E, Ghorashian S, Vormoor B, De Moerloose B, Bodmer N, Molostova O, et al. CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study. Leukemia. 2022;36(6):1525\u201332.","journal-title":"Leukemia"},{"issue":"4","key":"6608_CR43","doi-asserted-by":"publisher","first-page":"e410","DOI":"10.1016\/j.clml.2020.12.009","volume":"21","author":"L Zhang","year":"2021","unstructured":"Zhang L, Zuo Y, Lu A, Wu J, Jia Y, Wang Y, et al. Safety and efficacy of chimeric antigen receptor T-cell therapy in children with central nervous system leukemia. Clin Lymphoma Myeloma Leuk. 2021;21(4):e410\u20134.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"6608_CR44","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018;8(8):958\u201371.","journal-title":"Cancer Discov"},{"issue":"12","key":"6608_CR45","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s40263-018-0582-9","volume":"32","author":"J Gust","year":"2018","unstructured":"Gust J, Taraseviciute A, Turtle CJ. Neurotoxicity associated with CD19-targeted CAR-T cell therapies. CNS Drugs. 2018;32(12):1091\u2013101.","journal-title":"CNS Drugs"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06608-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06608-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06608-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T16:03:36Z","timestamp":1748361816000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06608-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6608"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06608-x","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"9 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involves human participants and was approved by the Medical Ethics Committee of Nanfang Hospital of Southern Medical University (Approval No. NFEC-2020-098). Participants gave informed consent to participate in the study before taking part.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All subjects provided written informed consent before enrollment and samples and data from patients were processed following standard operating procedures approved by the Medical Ethics Committee of Nanfang Hospital of Southern Medical University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"594"}}